微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 47.89% | -8.8% | -3.76% | 79/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 49.76% | -7.57% | 2.23% | 71/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 48.67% | -12.84% | -5.85% | 71/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 51.69% | -1.41% | -1.55% | 75/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 52.51% | -0.8% | -2.46% | 73/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 53.83% | 1.27% | -3.59% | 72/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 55.84% | 1.97% | 6.5% | 61/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 52.43% | -0.16% | -0.95% | 72/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 52.93% | -2.29% | -0.42% | 69/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 53.16% | -1.87% | -2.92% | 69/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 54.76% | 2.99% | 4.27% | 67/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 52.52% | -5.66% | -3.06% | 81/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 54.17% | -2.96% | 0% | 71/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 54.17% | -3.44% | 1.89% | 73/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 53.17% | -3.11% | -4.49% | 74/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 55.66% | 2.61% | -0.29% | 74/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 55.82% | 0.25% | -0.49% | 64/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 56.1% | 4.06% | 2.23% | 69/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 54.87% | 7.63% | 1.16% | 66/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 54.25% | -9.86% | -2.58% | 73/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 55.68% | -8.11% | 3.29% | 61/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 53.91% | -10.01% | 5.74% | 66/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 50.98% | -12.55% | -15.29% | 62/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 60.18% | 1.04% | -0.69% | 59/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 60.6% | 2.46% | 1.15% | 45/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 59.91% | 2.44% | 2.76% | 50/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 58.3% | 0.67% | -2.12% | 45/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 59.56% | 16.09% | 0.71% | 55/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 59.14% | 24.33% | 1.13% | 41/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 58.48% | 30.98% | 0.99% | 41/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 57.91% | 32.17% | 12.87% | 41/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 51.31% | 18.43% | 7.87% | 62/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 47.57% | 14.53% | 6.53% | 49/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 44.65% | 7.51% | 1.9% | 55/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 43.82% | 4.38% | 1.13% | 46/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 43.33% | 3.25% | 4.32% | 61/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 41.53% | 0.82% | 0% | 44/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 41.53% | 1.15% | -1.06% | 48/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 41.98% | 1.48% | 0.04% | 40/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |